Jess Roper - 03 Feb 2026 Form 4 Insider Report for REVELATION BIOSCIENCES, INC. (REVB)

Reporting relationship: Director
Issuer ticker: REVB
Reported as of: 03 Feb 2026
Net transaction value: -$2,943
SEC form: 4
Accepted by SEC: 05 Feb 2026, 17:31:20 UTC
Prior SEC filing: 12 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ J.P. Galda, as attorney-in-fact for Jess Roper

Key filing fact

Jess Roper filed Form 4 for REVELATION BIOSCIENCES, INC. (REVB) on 05 Feb 2026.

Key facts

This page summarizes Jess Roper's Form 4 filing for REVELATION BIOSCIENCES, INC. (REVB).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Feb 2026, 17:31.

Change

Previous filing in this sequence was filed on 12 Jan 2026.
Current net transaction value: -$2,943.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001408993 Primary reporting owner

ROPER JESS

Relationship: Director
Address: C/O REVELATION BIOSCIENCES, INC., 4660 LA JOLLA VILLAGE DR., SUITE 100, SAN DIEGO
Signature: /s/ J.P. Galda, as attorney-in-fact for Jess Roper
Signature date: 05 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

REVB transaction

Common Stock

Tax liability

Transaction value: $2,943
Shares: -1,591
Change %: -11%
Price: $1.85
Shares after: 12,828
Date: 03 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

Footnote F2

Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.88, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.